Cargando…

Non-Invasive Risk Stratification in NAFLD/NASH Patients for Screening EGD

Detalles Bibliográficos
Autores principales:	Romano, John, Abdelfattah, Thaer, Manka, Paul P, Fuchs, Michael, Syn, Wing-Kin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759994/ https://www.ncbi.nlm.nih.gov/pubmed/35046690 http://dx.doi.org/10.2147/CEG.S339850

Ejemplares similares

NASH, Metabolic Syndrome, and Diabetes: How Sugar and Fat Increase the Risk of Developing Advanced Liver Disease
por: Manka, Paul, et al.
Publicado: (2020)

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Circulatory Endothelin 1-Regulating RNAs Panel: Promising Biomarkers for Non-Invasive NAFLD/NASH Diagnosis and Stratification: Clinical and Molecular Pilot Study
por: Albadawy, Reda, et al.
Publicado: (2021)

EGD core curriculum
por: Kwon, Richard S., et al.
Publicado: (2017)

Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4
por: John, Katharina, et al.
Publicado: (2022)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Lifestyle modification in NAFLD/NASH: Facts and figures
por: Hallsworth, Kate, et al.
Publicado: (2019)

Diet and exercise in NAFLD/NASH: Beyond the obvious
por: Semmler, Georg, et al.
Publicado: (2021)

Patient-reported outcomes in NAFLD/NASH clinical trials: A blind spot that needs addressing
por: Sena, Elena, et al.
Publicado: (2022)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Colognesi, Martina, et al.
Publicado: (2020)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Improved pathology reporting in NAFLD/NASH for clinical trials
por: Langford, Caitlin Rose, et al.
Publicado: (2022)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
por: Finan, Brian, et al.
Publicado: (2020)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH()
por: Vachher, Meenakshi, et al.
Publicado: (2022)

Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
por: Finotti, Michele, et al.
Publicado: (2021)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

Role of Preoperative Esophagogastroduodenoscopy (EGD) in Bariatric Treatment
por: Sierżantowicz, Regina, et al.
Publicado: (2021)

EGD for Refractory Toxidromes: Is It Time to Add to the Algorithm?
por: Allen, Kelsey, et al.
Publicado: (2022)

Comparison of Widely Used Listeria monocytogenes Strains EGD, 10403S, and EGD-e Highlights Genomic Differences Underlying Variations in Pathogenicity
por: Bécavin, Christophe, et al.
Publicado: (2014)

Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
por: Mahmoudi, Ali, et al.
Publicado: (2022)

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
por: Xu, Gao-Xin, et al.
Publicado: (2023)

A Review of the Epidemiology, Pathophysiology, and Efficacy of Anti-diabetic Drugs Used in the Treatment of Nonalcoholic Fatty Liver Disease
por: Manka, Paul P., et al.
Publicado: (2021)

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations
por: Adinolfi, Luigi Elio, et al.
Publicado: (2016)

SAT-LB004 Therapeutic Potential of LPCN 1144 in NAFLD and NASH
por: Baker, Jonathan, et al.
Publicado: (2019)

Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
por: Svegliati-Baroni, Gianluca, et al.
Publicado: (2020)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
por: Carreres, Lydie, et al.
Publicado: (2021)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
por: Piras, Cristina, et al.
Publicado: (2021)

Comprehensive Transcriptome Profiling of NAFLD- and NASH-Induced Skeletal Muscle Dysfunction
por: Guo, Mingwei, et al.
Publicado: (2022)

Analysis of the Patient Information Quality and Readability on Esophagogastroduodenoscopy (EGD) on the Internet
por: Priyanka, P., et al.
Publicado: (2018)

Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
por: Dongiovanni, Paola, et al.
Publicado: (2013)

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
por: Kořínková, L., et al.
Publicado: (2020)

Effect of exercise and diet intervention in NAFLD and NASH via GAB2 methylation
por: Wu, Na, et al.
Publicado: (2021)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
por: Gabbia, Daniela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0oai9mn08o36fq4qsb8fjko3oq